245 related articles for article (PubMed ID: 33617821)
1. Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer.
Jaromy M; Miller JD
Eur J Pharmacol; 2021 Apr; 897():173956. PubMed ID: 33617821
[TBL] [Abstract][Full Text] [Related]
2. Metformin, Microbiome and Protection Against Colorectal Cancer.
Jones GR; Molloy MP
Dig Dis Sci; 2021 May; 66(5):1409-1414. PubMed ID: 32533543
[TBL] [Abstract][Full Text] [Related]
3. One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metformin.
Menendez JA; Joven J
Aging (Albany NY); 2012 Dec; 4(12):894-8. PubMed ID: 23525940
[TBL] [Abstract][Full Text] [Related]
4. Metformin: multi-faceted protection against cancer.
Del Barco S; Vazquez-Martin A; Cufí S; Oliveras-Ferraros C; Bosch-Barrera J; Joven J; Martin-Castillo B; Menendez JA
Oncotarget; 2011 Dec; 2(12):896-917. PubMed ID: 22203527
[TBL] [Abstract][Full Text] [Related]
5. Metformin: Insights into its anticancer potential with special reference to AMPK dependent and independent pathways.
Ikhlas S; Ahmad M
Life Sci; 2017 Sep; 185():53-62. PubMed ID: 28755883
[TBL] [Abstract][Full Text] [Related]
6. Repurposing old drugs to chemoprevention: the case of metformin.
Heckman-Stoddard BM; Gandini S; Puntoni M; Dunn BK; DeCensi A; Szabo E
Semin Oncol; 2016 Feb; 43(1):123-133. PubMed ID: 26970131
[TBL] [Abstract][Full Text] [Related]
7. Metformin mediated reversal of epithelial to mesenchymal transition is triggered by epigenetic changes in E-cadherin promoter.
Banerjee P; Surendran H; Chowdhury DR; Prabhakar K; Pal R
J Mol Med (Berl); 2016 Dec; 94(12):1397-1409. PubMed ID: 27534967
[TBL] [Abstract][Full Text] [Related]
8. The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway.
Li B; Takeda T; Tsuiji K; Kondo A; Kitamura M; Wong TF; Yaegashi N
Gynecol Endocrinol; 2013 Jan; 29(1):87-90. PubMed ID: 22835064
[TBL] [Abstract][Full Text] [Related]
9. Metformin is synthetically lethal with glucose withdrawal in cancer cells.
Menendez JA; Oliveras-Ferraros C; Cufí S; Corominas-Faja B; Joven J; Martin-Castillo B; Vazquez-Martin A
Cell Cycle; 2012 Aug; 11(15):2782-92. PubMed ID: 22809961
[TBL] [Abstract][Full Text] [Related]
10. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth.
Hirsch HA; Iliopoulos D; Struhl K
Proc Natl Acad Sci U S A; 2013 Jan; 110(3):972-7. PubMed ID: 23277563
[TBL] [Abstract][Full Text] [Related]
11. Combined use of vitamin D3 and metformin exhibits synergistic chemopreventive effects on colorectal neoplasia in rats and mice.
Li W; Wang QL; Liu X; Dong SH; Li HX; Li CY; Guo LS; Gao JM; Berger NA; Li L; Ma L; Wu YJ
Cancer Prev Res (Phila); 2015 Feb; 8(2):139-48. PubMed ID: 25416412
[TBL] [Abstract][Full Text] [Related]
12. Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer.
Menendez JA; Cufí S; Oliveras-Ferraros C; Martin-Castillo B; Joven J; Vellon L; Vazquez-Martin A
Aging (Albany NY); 2011 Nov; 3(11):1063-77. PubMed ID: 22170748
[TBL] [Abstract][Full Text] [Related]
13. Metformin - its potential anti-cancer and anti-aging effects.
Podhorecka M; Ibanez B; Dmoszyńska A
Postepy Hig Med Dosw (Online); 2017 Mar; 71(0):170-175. PubMed ID: 28258677
[TBL] [Abstract][Full Text] [Related]
14. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Martin-Castillo B; Joven J; Menendez JA
Cell Cycle; 2010 Nov; 9(22):4461-8. PubMed ID: 21088486
[TBL] [Abstract][Full Text] [Related]
15. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.
Hosono K; Endo H; Takahashi H; Sugiyama M; Uchiyama T; Suzuki K; Nozaki Y; Yoneda K; Fujita K; Yoneda M; Inamori M; Tomatsu A; Chihara T; Shimpo K; Nakagama H; Nakajima A
Mol Carcinog; 2010 Jul; 49(7):662-71. PubMed ID: 20564343
[TBL] [Abstract][Full Text] [Related]
16. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Zheng G; Qiu Z
Toxicol Appl Pharmacol; 2019 Feb; 365():51-60. PubMed ID: 30625338
[TBL] [Abstract][Full Text] [Related]
17. Metformin Inhibits Cellular Proliferation and Bioenergetics in Colorectal Cancer Patient-Derived Xenografts.
Mohamed Suhaimi NA; Phyo WM; Yap HY; Choy SHY; Wei X; Choudhury Y; Tan WJ; Tan LAPY; Foo RSY; Tan SHS; Tiang Z; Wong CF; Koh PK; Tan MH
Mol Cancer Ther; 2017 Sep; 16(9):2035-2044. PubMed ID: 28533437
[TBL] [Abstract][Full Text] [Related]
18. The regulatory effects of metformin on the [SNAIL/miR-34]:[ZEB/miR-200] system in the epithelial-mesenchymal transition(EMT) for colorectal cancer(CRC).
Wang Y; Wu Z; Hu L
Eur J Pharmacol; 2018 Sep; 834():45-53. PubMed ID: 30017802
[TBL] [Abstract][Full Text] [Related]
19. Metformin attenuates albumin-induced alterations in renal tubular cells in vitro.
Allouch S; Munusamy S
J Cell Physiol; 2017 Dec; 232(12):3652-3663. PubMed ID: 28158902
[TBL] [Abstract][Full Text] [Related]
20. Metformin: from mechanisms of action to therapies.
Foretz M; Guigas B; Bertrand L; Pollak M; Viollet B
Cell Metab; 2014 Dec; 20(6):953-66. PubMed ID: 25456737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
